Paper Details

  1. Home
  2. Paper Details

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.

Author: BrayRoss, DahlDominik, HuhRuth, NorwoodPaul, OnishiYukiko, PatelHiren, RodríguezÁngel

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 3 clinical trial assessed the efficacy and safety of tirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control. Tirzepatide significantly improved glycemic control, as measured by HbA1c, compared to placebo after 40 weeks. It also resulted in significant weight loss. The most common adverse events were diarrhea and nausea. Tirzepatide is a promising treatment option for patients with type 2 diabetes who have inadequate glycemic control despite insulin glargine therapy.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described. OBJECTIVE: To assess the efficacy and safety of tirzepatide added to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826179/

データ提供：米国国立医学図書館（NLM）

Tirzepatide: A New Oasis in the Desert of Type 2 Diabetes Treatment

Type 2 diabetes, a chronic metabolic disorder, is like a desert stretching as far as the eye can see, posing a significant health challenge. This 2021 study investigated the effectiveness of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, as an add-on to insulin glargine for the treatment of type 2 diabetes. It was a large randomized clinical trial, like a caravan of researchers traversing the desert to collect data. The study found that tirzepatide, when added to insulin glargine, significantly improved glycemic control in patients with type 2 diabetes who were not achieving adequate control with insulin glargine alone. This discovery is like finding a hidden spring in the desert, bringing much-needed relief to those struggling with thirst.

Improved Glycemic Control and Weight Loss: A Double Oasis

The researchers observed a significant reduction in HbA1c levels (a measure of blood sugar control) and body weight in patients treated with tirzepatide compared to those receiving placebo. This is like finding a double oasis, providing both hydration and a source of nourishment. The study also found that a higher percentage of patients treated with tirzepatide achieved HbA1c levels less than 7%, which is a significant improvement in blood sugar control. These findings hold great promise for those living with type 2 diabetes, offering a glimpse of a healthier future.

A Beacon of Hope for Diabetes Management

This study is a beacon of hope for those struggling with type 2 diabetes, like a star guiding travelers through the desert. It provides compelling evidence that tirzepatide can effectively improve glycemic control and potentially lead to weight loss, bringing us closer to a more manageable future for those living with this chronic condition.

Dr.Camel's Conclusion

This study highlights the potential of tirzepatide as a promising new treatment for type 2 diabetes, offering a new oasis in the desert of chronic health challenges. It's a welcome discovery, like finding a hidden spring in the desert, giving hope for a healthier and more fulfilling life.

Date :
  1. Date Completed 2022-02-17
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

35133415

DOI: Digital Object Identifier

PMC8826179

Related Literature

Article Analysis
・Effects of tirzepatide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.